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Basic Mechanisms of Apoptosis
and the Role of Akt
Apoptosis is a highly controlled cellular suicide program
that plays an important role in a wide range of processes
including morphogenesis, immune-cell homeostasis, and
immune self-tolerance. Two major apoptotic pathways have
been described: the extrinsic pathway that involves activa-
tion of a death receptor on the cell surface, and the intrinsic
pathway that engages intracellular pro-apoptotic proteins
such as Bax, Puma, Noxa, and others (see Fig 1). Both
pathways converge on the mitochondria to induce release
of cytochrome c and several other proteins from the mi-
tochondrial intermembrane space to the cytosol. These
factors promote the activation of caspase-9 and suppress
the inhibitor of apoptosis proteins (IAPS) to stimulate down-
stream executioner caspases that, in turn, carry out
apoptosis. In the extrinsic pathway, depending on the cell
type, activation of caspase-8 may either directly induce cell
death by activating the terminal caspases (type I cells), or
recruit the mitochondrial pathway of cytochrome c release
and caspase-9 activation (type II cells). In both cases ca-
spase-8 activation is required for the execution of apopto-
sis. In the extrinsic pathway, activation of the death
receptors by natural ligands induces apoptosis in several
cell types. Fas receptor is a ubiquitously expressed recep-
tor that belongs to the tumor necrosis factor a (TNFa) re-
ceptor/nerve growth factor receptor family and triggers
caspase-8 activation through involvement of Fas-associat-
ed protein with death domain. In healthy cells, the effect of
the pro-apoptotic factors is balanced by anti-apoptotic
proteins such as Bcl-2, Bcl-xL, and Mcl-1, which by acting
on the mitochondria inhibit the release of apoptogenic mol-
ecules (Martin and Elkon, 2004).
One of the key enzymes in the regulation of apoptosis is
Akt (protein kinase B). This 60 kDa serine/threonine kinase
is expressed in most cell types and appears to inhibit both
spontaneous and stress-induced apoptosis. Akt is activated
by numerous factors including insulin-like growth factor-1
(IGF-1) and BDNF using the phosphatidylinositol 3-kinase
(PI3K)-generated polyphospho-phosphatidylinositols (Datta
et al, 1999). During the activation, Akt is phosphorylated (p-
Akt), a process achieved at least in part by phosphoinosi-
tide-dependent protein kinase-1 (PDK-1) (Brunet et al,
2001). It has been demonstrated that transfection of a va-
riety of cell types with constitutively active Akt alleles
blocked apoptosis induced by various apoptotic stimuli in-
cluding anti-Fas antibody and transforming growth factor-b
(TGF-b) (Datta et al, 1999). Akt is postulated to inhibit
apoptosis both up- and downstream of the mitochondrial
phase (Fig 2). Akt activity may result in the inhibition of pro-
apoptotic Bad, Bax, Bik, and caspase-9 by phosphorylat-
ion. Akt activation also promotes the upregulation of
transcription factors such as cAMP-responsive element-
binding protein (CREB) and the nuclear factor-kB (NF-kB)
regulator IKK (Datta et al, 1999; Juin et al, 1999; Kennedy
et al, 1999).
Indirect immunofluorescence microscopy revealed colo-
calization of Akt and Bad (Blume-Jensen et al, 1998). Akt
phosphorylates Bad to suppress the Bad-dependent cyto-
chrome c release from the mitochondria (Blume-Jensen
et al, 1998; Datta et al, 1999). Notably, Akt can also block
the release of cytochrome c from mitochondria in cells that
lack Bad (Juin et al, 1999), as well as block cell death in-
duced by Bax and Bid (Kennedy et al, 1999). Evidence has
recently emerged that Akt also phophorylates caspase-9
to attenuate the caspase activation downstream of cyto-
chrome c release (Datta et al, 1999). In the presence of
survival factors, activated Akt phosphorylates the Forkhead
family members (such as FOXO), resulting in their seques-
tration in the cytoplasm. In the absence of survival factors
and Akt activity, the Forkhead family members translocate
to the nucleus and initiate expression of various ‘‘death’’
genes (FasL, Fas, TNFa, TNFR), which, in turn, promote cell
death. Growth factors may also be able to prevent cell
death by upregulating genes that are capable of promoting
cell survival. Akt can associate in vivo with the IKKa
and b kinases, which promote the degradation of IkB.
Degradation of IkB results in the nuclear translocation
of NF-kB and subsequent activation of its target genes.
These genes are yet to be identified but may include pro-
survival Bcl-2 family member Bfl-1/A1 and certain caspase
inhibitors.
Akt also mediates the effect of insulin and IGF-1 on cell
metabolism. In this signaling cascade, Akt phosphorylates
and inactivates glycogen synthase kinase-3 (GSK-3), a
process that affects metabolism and that, in turn, may pro-
mote cell survival. However, Akt has several other substrates
that have not yet been implicated in growth factor-mediated
cell survival. It is also noteworthy that Akt can block
Fas-mediated apoptosis by a mechanism that is not
explained by the phosphorylation of any of the known
substrates.
Abbreviations: BDNF, brain-derived neurotrophic factor; PI3K,
phosphatidylinositol 3-kinase; SSc, systemic sclerosis; TGF-b,
transforming growth factor-b
Copyright r 2005 by The Society for Investigative Dermatology, Inc.
viii
Figure 1
Extrinsic and intrinsic pathways of apoptosis (schematic presentation).
Figure 2
Phosphatidylinositol 3-kinase (PI3K/Akt)-related substrates and their role in cell survival (schematic presentation).
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It has been postulated that TGF-b may activate
PI3K in epithelial cells and fetal rat hepatocytes to promote cell
survival via Akt-dependent regulation (Valdes et al, 2004).
It has also been demonstrated that in kidney mesangial
cells TGF-b1 is able to activate PDK-1 and Akt. Blockage of
the PI3K or Akt abrogated the TGF-b1-stimulated COL1A2
gene transcription. The inhibition of the PI3K pathway re-
sulted in diminished Smad3 activity, indicating a possible
cross-talk between Smad and PI3K/Akt pathways in the
regulation of type I collagen expression in response to TGF-
b (Runyan et al, 2004).
Role of Akt in Rheumatic Diseases
Although the role of apoptotic pathways in the pathogenesis
of rheumatic/autoimmune diseases has been extensively
investigated, the role of Akt has previously only been studied
in rheumatoid arthritis. Evidence has emerged to indicate
that Akt may play a role in the pathogenesis of rheumatoid
arthritis. In macrophages isolated from rheumatoid arthritis-
affected joints, apoptosis was induced following inhibition
of the PI3K/Akt pathway (Perlman et al, 2001). In rheumatoid
arthritis synovial fibroblasts, higher levels of activated
Akt were detected and treatment with TNFa-induced Akt
activation. Inhibition of PI3K allowed TNFa to induce
synovial fibroblast apoptosis (Zhang et al, 2001), and
more recent studies revealed the PI3K/Akt pathway involve-
ment in the TGF-b-mediated growth and anti-apoptotic
effects in synovial rheumatoid arthritis fibroblasts (Kim et al,
2002).
Significance of Apoptosis in Systemic
Sclerosis (SSc) Fibroblasts
The most remarkable pathologic alterations in SSc are
caused by the exaggerated deposition of interstitial colla-
gens (mainly type I), and other extracellular matrix compo-
nents in affected tissues. Inflammatory elements including
mononuclear cells such as macrophages and T cells also
play a role. These inflammatory cells produce numerous
factors among which TGF-b appears to play a pivotal role
in the pathogenesis of SSc (Jimenez and Derk, 2004). The
TGF-b-activated fibroblasts induce further production of
TGF-b by an autocrine signaling mechanism and also ex-
press increased levels of TGF-b receptors. The binding of
activated TGF-b by phosphorylation of its receptor forms
an active receptor complex on the target cell. Subsequent
signaling to the nucleus occurs through the Smad family of
proteins.
Although it has been recognized that the pathology of SSc
primarily involves activation of fibroblasts, it has only recently
been discovered that SSc fibroblasts are resistant to certain
forms of programmed cell death. Two recent studies have
shown that SSc fibroblasts are more resistant to Fas-medi-
ated apoptosis compared with control fibroblasts (Jelaska
and Korn, 2000; Santiago et al, 2001). Following sustained
exposure to TGF-b, SSc fibroblasts became resistant to
anti-Fas antibody-induced apoptosis and also displayed
increased proliferation. Defective apoptosis was not linked
to a ubiquitous element of the apoptotic pathways because
staurosporine, a non-specific protein kinase inhibitor,
induced cell death similarly in SSc and normal fibroblasts.
It is noteworthy that the downregulation of Bcl-2 expression
caused increased susceptibility to TGF-b-induced apop-
tosis in SSc fibroblasts, suggesting a role of Bcl-2 in the
development of apoptosis resistance (Santiago et al, 2001).
The current issue of Journal of Investigative Dermatology
features a study by Jun et al examining the potential role of
Akt in the resistance of SSc fibroblasts to cell death. In
vitro experiments found a relatively high level of p-Akt
in SSc fibroblasts and showed an elevated activity of
this anti-apoptotic factor in GSK-3 phosphorylation. When
the number of fibroblasts expressing p-Akt was quantitated
in skin biopsies, more cells stained positive for p-Akt in
SSc than in control skin, further supporting an elevation
of p-Akt in SSc fibroblasts. The authors were able to dem-
onstrate the expression of both p-Akt and a smooth muscle
actin (SMA-a) in one of three samples studied. The pres-
ence of SMA-a indicates fibroblast–myofibroblast trans-
differentiation, possibly induced by TGF-b as it has been
described in other studies. The relationship between such
a transdifferentiation process and the occurrence of
p-Akt expression is a very important and relevant sugges-
tion that requires further confirmatory studies. Although in
the study of Jun et al TGF-b-induced Akt activation was
shown in SSc fibroblasts, this finding did not reach a sta-
tistically significant difference when compared with normal
fibroblasts.
In this regard, it may be important to examine whether
blocking TGF-b activity either with specific antibodies or by
blockade of its receptor can abrogate the difference in the
level of p-Akt observed between SSc and normal fibro-
blasts. It is also possible that the Akt activation in SSc
fibroblasts involves not only TGF-b also other factors
(cytokines, ligands, etc.) that have also been identified to
play a role in the pathophysiology of SSc. Further studies
should address the potential role of these factors in the
upregulation of p-Akt. The other emerging question is
whether the presence of activated Akt indeed brings about
prolonged SSc fibroblast survival. Alteration in SSc fibro-
blast survival needs to be determined in the presence and
absence of activated Akt. In case that the occurrence of
elevated p-Akt is indeed associated with attenuated
apoptosis of SSc fibroblasts, downstream elements of the
apoptotic pathway related to Akt should be examined to
identify the factors that mediate the Akt activity. Jun et al’s
study is an important step in the investigation of the patho-
physiology of SSc fibroblast resistance to apoptosis. This
study raises several provocative questions and also rein-
forces the potential role of altered cell death in this severe
autoimmune disease. Every step that brings us closer to
understand the complex pathophysiology of SSc is there-
fore extremely welcome and undoubtedly will lead us closer
to the development of effective therapy for this devastating
and, to date, incurable disease.
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